Project Grant R21CA309360
Award Date 4/10/26
Completion Date 3/31/27
Dollars Obligated $385K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This five-year award supports research into the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease that claims over 52,000 lives annually in the United...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $624,194 under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2031. This five-year award supports fundamental research investigating how the integrated stress response (ISR) regulates CD8+ tumor-infiltrating lymphocyte (TIL) function and immunometabolism within the tumor microenvironment (TME). The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $166,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2028. This award supports fundamental research investigating mechanisms of resistance to KRAS inhibitors in pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90% of cases driven by KRAS mutations. The project delivers...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $661,721 Project Grant to the University of California, San Diego, with an award date of April 1, 2026, and a completion date of March 31, 2031. This five-year research initiative focuses on systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The project will utilize novel high-throughput...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $119,858 to the Regents of the University of Minnesota under the Cancer Biology Research program (CFDA 93.396) on August 7, 2025, for a project extending through July 31, 2030. This project grant supports fundamental research aimed at elucidating and overcoming T cell dysfunction in pancreatic ductal adenocarcinoma (PDA), a disease notoriously resistant to immunotherapy. The research program comprises three...
- Federal Grant Award Summary The University of North Carolina at Asheville received a $428,396 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2029. This three-year award supports fundamental research investigating novel post-translational regulatory mechanisms of G12/13 heterotrimeric G proteins, which have been implicated in driving tumorigenic signaling, metastatic invasiveness, and stem...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 5, 2025, with a completion date of August 31, 2027. This research initiative addresses the identification and validation of noncovalent protein interactions associated with mutant KRAS (MKRAS) inhibitors, building upon recent advances in KRAS G12C-targeted therapeutics that have achieved FDA...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...